Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction
Thiazolidinedione is a five-membered heterocycle that is widely used in drug discovery endeavors. In this study, we report the design, synthesis, and biological evaluation of a series of thiazolidinedione-based HDAC6 inhibitors. In particular, compound exerts an excellent inhibitory activity against...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2019-12, Vol.20 (24), p.6213 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 24 |
| container_start_page | 6213 |
| container_title | International journal of molecular sciences |
| container_volume | 20 |
| creator | Sharma, Chiranjeev Oh, Yong Jin Park, Byoungduck Lee, Sooyeun Jeong, Chul-Ho Lee, Sangkil Seo, Ji Hae Seo, Young Ho |
| description | Thiazolidinedione is a five-membered heterocycle that is widely used in drug discovery endeavors. In this study, we report the design, synthesis, and biological evaluation of a series of thiazolidinedione-based HDAC6 inhibitors. In particular, compound
exerts an excellent inhibitory activity against HDAC6 with an IC
value of 21 nM, displaying a good HDAC6 selectivity over HDAC1. Compound
dose-dependently induces the acetylation level of
-tubulin via inhibition of HDAC6 in human neuroblastoma SH-SY5Y cell line. Moreover, compound
efficiently reverses methamphetamine-induced morphology changes of SH-SY5Y cells via regulating acetylation landscape of
-tubulin. Collectively, compound
represents a novel HDAC6-isoform selective inhibitor and demonstrates promising therapeutic potential for the treatment of methamphetamine addiction. |
| doi_str_mv | 10.3390/ijms20246213 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6940941</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2336250932</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-22cbda1f8dfd840e2322759c58901497e9bd7ba6141488e8fe6a301831f45d083</originalsourceid><addsrcrecordid>eNpdkc1L7DAUxYMo6lN3rqXgxoXVfDVNNsI4895TUNzoUkLa3NoMbTMmnQH96434wejqXri_c7iHg9AhwWeMKXzu5n2kmHJBCdtAu4RTmmMsys21fQf9iXGOMWW0UNtohxHJCibVLnqcwQo6v-hhGDPfZPetM6--c9YNYJ0fIL80EWx2NZtMRXY9tK5yow8xG312t4JQ-x6yWxhb0y9aGE2fdNnEWlePSb2PthrTRTj4nHvo4d_f--lVfnP3_3o6uclrXsoxp7SurCGNtI2VHEN6k5aFqgupMOGqBFXZsjKCcMKlBNmAMAynDKThhcWS7aGLD9_FsurB1ilMMJ1eBNeb8KK9cfrnZXCtfvIrLRTHipNkcPJpEPzzEuKoexdr6DozgF9GTRkTtMCK0YQe_0LnfhmGFE_TgkshSkXLRJ1-UHXwMQZovp8hWL_3ptd7S_jReoBv-Kso9gYuz5Qd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548667927</pqid></control><display><type>article</type><title>Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction</title><source>PubMed (Medline)</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Sharma, Chiranjeev ; Oh, Yong Jin ; Park, Byoungduck ; Lee, Sooyeun ; Jeong, Chul-Ho ; Lee, Sangkil ; Seo, Ji Hae ; Seo, Young Ho</creator><creatorcontrib>Sharma, Chiranjeev ; Oh, Yong Jin ; Park, Byoungduck ; Lee, Sooyeun ; Jeong, Chul-Ho ; Lee, Sangkil ; Seo, Ji Hae ; Seo, Young Ho</creatorcontrib><description>Thiazolidinedione is a five-membered heterocycle that is widely used in drug discovery endeavors. In this study, we report the design, synthesis, and biological evaluation of a series of thiazolidinedione-based HDAC6 inhibitors. In particular, compound
exerts an excellent inhibitory activity against HDAC6 with an IC
value of 21 nM, displaying a good HDAC6 selectivity over HDAC1. Compound
dose-dependently induces the acetylation level of
-tubulin via inhibition of HDAC6 in human neuroblastoma SH-SY5Y cell line. Moreover, compound
efficiently reverses methamphetamine-induced morphology changes of SH-SY5Y cells via regulating acetylation landscape of
-tubulin. Collectively, compound
represents a novel HDAC6-isoform selective inhibitor and demonstrates promising therapeutic potential for the treatment of methamphetamine addiction.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms20246213</identifier><identifier>PMID: 31835389</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Acetylation ; Addictions ; Amphetamine-Related Disorders - drug therapy ; Amphetamine-Related Disorders - enzymology ; Cell Line, Tumor ; Cytology ; Cytoskeleton ; Cytotoxicity ; Drug development ; Drug Discovery ; Drug dosages ; Enzymes ; Epigenetics ; Histone Deacetylase 6 - antagonists & inhibitors ; Histone Deacetylase 6 - chemistry ; Histone Deacetylase 6 - metabolism ; Histone Deacetylase Inhibitors - chemical synthesis ; Histone Deacetylase Inhibitors - chemistry ; Histone Deacetylase Inhibitors - pharmacology ; Humans ; Inhibitors ; Isoenzymes - antagonists & inhibitors ; Isoenzymes - chemistry ; Isoenzymes - metabolism ; Methamphetamine ; Morphology ; Proteins ; Selectivity ; Thiazolidinediones - chemical synthesis ; Thiazolidinediones - chemistry ; Thiazolidinediones - pharmacology ; Tubulin</subject><ispartof>International journal of molecular sciences, 2019-12, Vol.20 (24), p.6213</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-22cbda1f8dfd840e2322759c58901497e9bd7ba6141488e8fe6a301831f45d083</citedby><cites>FETCH-LOGICAL-c478t-22cbda1f8dfd840e2322759c58901497e9bd7ba6141488e8fe6a301831f45d083</cites><orcidid>0000-0002-5515-2197</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940941/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940941/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31835389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sharma, Chiranjeev</creatorcontrib><creatorcontrib>Oh, Yong Jin</creatorcontrib><creatorcontrib>Park, Byoungduck</creatorcontrib><creatorcontrib>Lee, Sooyeun</creatorcontrib><creatorcontrib>Jeong, Chul-Ho</creatorcontrib><creatorcontrib>Lee, Sangkil</creatorcontrib><creatorcontrib>Seo, Ji Hae</creatorcontrib><creatorcontrib>Seo, Young Ho</creatorcontrib><title>Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Thiazolidinedione is a five-membered heterocycle that is widely used in drug discovery endeavors. In this study, we report the design, synthesis, and biological evaluation of a series of thiazolidinedione-based HDAC6 inhibitors. In particular, compound
exerts an excellent inhibitory activity against HDAC6 with an IC
value of 21 nM, displaying a good HDAC6 selectivity over HDAC1. Compound
dose-dependently induces the acetylation level of
-tubulin via inhibition of HDAC6 in human neuroblastoma SH-SY5Y cell line. Moreover, compound
efficiently reverses methamphetamine-induced morphology changes of SH-SY5Y cells via regulating acetylation landscape of
-tubulin. Collectively, compound
represents a novel HDAC6-isoform selective inhibitor and demonstrates promising therapeutic potential for the treatment of methamphetamine addiction.</description><subject>Acetylation</subject><subject>Addictions</subject><subject>Amphetamine-Related Disorders - drug therapy</subject><subject>Amphetamine-Related Disorders - enzymology</subject><subject>Cell Line, Tumor</subject><subject>Cytology</subject><subject>Cytoskeleton</subject><subject>Cytotoxicity</subject><subject>Drug development</subject><subject>Drug Discovery</subject><subject>Drug dosages</subject><subject>Enzymes</subject><subject>Epigenetics</subject><subject>Histone Deacetylase 6 - antagonists & inhibitors</subject><subject>Histone Deacetylase 6 - chemistry</subject><subject>Histone Deacetylase 6 - metabolism</subject><subject>Histone Deacetylase Inhibitors - chemical synthesis</subject><subject>Histone Deacetylase Inhibitors - chemistry</subject><subject>Histone Deacetylase Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Isoenzymes - antagonists & inhibitors</subject><subject>Isoenzymes - chemistry</subject><subject>Isoenzymes - metabolism</subject><subject>Methamphetamine</subject><subject>Morphology</subject><subject>Proteins</subject><subject>Selectivity</subject><subject>Thiazolidinediones - chemical synthesis</subject><subject>Thiazolidinediones - chemistry</subject><subject>Thiazolidinediones - pharmacology</subject><subject>Tubulin</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1L7DAUxYMo6lN3rqXgxoXVfDVNNsI4895TUNzoUkLa3NoMbTMmnQH96434wejqXri_c7iHg9AhwWeMKXzu5n2kmHJBCdtAu4RTmmMsys21fQf9iXGOMWW0UNtohxHJCibVLnqcwQo6v-hhGDPfZPetM6--c9YNYJ0fIL80EWx2NZtMRXY9tK5yow8xG312t4JQ-x6yWxhb0y9aGE2fdNnEWlePSb2PthrTRTj4nHvo4d_f--lVfnP3_3o6uclrXsoxp7SurCGNtI2VHEN6k5aFqgupMOGqBFXZsjKCcMKlBNmAMAynDKThhcWS7aGLD9_FsurB1ilMMJ1eBNeb8KK9cfrnZXCtfvIrLRTHipNkcPJpEPzzEuKoexdr6DozgF9GTRkTtMCK0YQe_0LnfhmGFE_TgkshSkXLRJ1-UHXwMQZovp8hWL_3ptd7S_jReoBv-Kso9gYuz5Qd</recordid><startdate>20191209</startdate><enddate>20191209</enddate><creator>Sharma, Chiranjeev</creator><creator>Oh, Yong Jin</creator><creator>Park, Byoungduck</creator><creator>Lee, Sooyeun</creator><creator>Jeong, Chul-Ho</creator><creator>Lee, Sangkil</creator><creator>Seo, Ji Hae</creator><creator>Seo, Young Ho</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5515-2197</orcidid></search><sort><creationdate>20191209</creationdate><title>Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction</title><author>Sharma, Chiranjeev ; Oh, Yong Jin ; Park, Byoungduck ; Lee, Sooyeun ; Jeong, Chul-Ho ; Lee, Sangkil ; Seo, Ji Hae ; Seo, Young Ho</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-22cbda1f8dfd840e2322759c58901497e9bd7ba6141488e8fe6a301831f45d083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acetylation</topic><topic>Addictions</topic><topic>Amphetamine-Related Disorders - drug therapy</topic><topic>Amphetamine-Related Disorders - enzymology</topic><topic>Cell Line, Tumor</topic><topic>Cytology</topic><topic>Cytoskeleton</topic><topic>Cytotoxicity</topic><topic>Drug development</topic><topic>Drug Discovery</topic><topic>Drug dosages</topic><topic>Enzymes</topic><topic>Epigenetics</topic><topic>Histone Deacetylase 6 - antagonists & inhibitors</topic><topic>Histone Deacetylase 6 - chemistry</topic><topic>Histone Deacetylase 6 - metabolism</topic><topic>Histone Deacetylase Inhibitors - chemical synthesis</topic><topic>Histone Deacetylase Inhibitors - chemistry</topic><topic>Histone Deacetylase Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Isoenzymes - antagonists & inhibitors</topic><topic>Isoenzymes - chemistry</topic><topic>Isoenzymes - metabolism</topic><topic>Methamphetamine</topic><topic>Morphology</topic><topic>Proteins</topic><topic>Selectivity</topic><topic>Thiazolidinediones - chemical synthesis</topic><topic>Thiazolidinediones - chemistry</topic><topic>Thiazolidinediones - pharmacology</topic><topic>Tubulin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sharma, Chiranjeev</creatorcontrib><creatorcontrib>Oh, Yong Jin</creatorcontrib><creatorcontrib>Park, Byoungduck</creatorcontrib><creatorcontrib>Lee, Sooyeun</creatorcontrib><creatorcontrib>Jeong, Chul-Ho</creatorcontrib><creatorcontrib>Lee, Sangkil</creatorcontrib><creatorcontrib>Seo, Ji Hae</creatorcontrib><creatorcontrib>Seo, Young Ho</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sharma, Chiranjeev</au><au>Oh, Yong Jin</au><au>Park, Byoungduck</au><au>Lee, Sooyeun</au><au>Jeong, Chul-Ho</au><au>Lee, Sangkil</au><au>Seo, Ji Hae</au><au>Seo, Young Ho</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2019-12-09</date><risdate>2019</risdate><volume>20</volume><issue>24</issue><spage>6213</spage><pages>6213-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Thiazolidinedione is a five-membered heterocycle that is widely used in drug discovery endeavors. In this study, we report the design, synthesis, and biological evaluation of a series of thiazolidinedione-based HDAC6 inhibitors. In particular, compound
exerts an excellent inhibitory activity against HDAC6 with an IC
value of 21 nM, displaying a good HDAC6 selectivity over HDAC1. Compound
dose-dependently induces the acetylation level of
-tubulin via inhibition of HDAC6 in human neuroblastoma SH-SY5Y cell line. Moreover, compound
efficiently reverses methamphetamine-induced morphology changes of SH-SY5Y cells via regulating acetylation landscape of
-tubulin. Collectively, compound
represents a novel HDAC6-isoform selective inhibitor and demonstrates promising therapeutic potential for the treatment of methamphetamine addiction.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31835389</pmid><doi>10.3390/ijms20246213</doi><orcidid>https://orcid.org/0000-0002-5515-2197</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2019-12, Vol.20 (24), p.6213 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6940941 |
| source | PubMed (Medline); MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; EZB Electronic Journals Library |
| subjects | Acetylation Addictions Amphetamine-Related Disorders - drug therapy Amphetamine-Related Disorders - enzymology Cell Line, Tumor Cytology Cytoskeleton Cytotoxicity Drug development Drug Discovery Drug dosages Enzymes Epigenetics Histone Deacetylase 6 - antagonists & inhibitors Histone Deacetylase 6 - chemistry Histone Deacetylase 6 - metabolism Histone Deacetylase Inhibitors - chemical synthesis Histone Deacetylase Inhibitors - chemistry Histone Deacetylase Inhibitors - pharmacology Humans Inhibitors Isoenzymes - antagonists & inhibitors Isoenzymes - chemistry Isoenzymes - metabolism Methamphetamine Morphology Proteins Selectivity Thiazolidinediones - chemical synthesis Thiazolidinediones - chemistry Thiazolidinediones - pharmacology Tubulin |
| title | Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T00%3A21%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Thiazolidinedione-Based%20HDAC6%20Inhibitors%20to%20Overcome%20Methamphetamine%20Addiction&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Sharma,%20Chiranjeev&rft.date=2019-12-09&rft.volume=20&rft.issue=24&rft.spage=6213&rft.pages=6213-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms20246213&rft_dat=%3Cproquest_pubme%3E2336250932%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548667927&rft_id=info:pmid/31835389&rfr_iscdi=true |